Advertisement

Clinical Characteristics of Japanese Patients with Palmoplantar Pustulosis

  • Toshiyuki YamamotoEmail author
Review Article
  • 21 Downloads

Abstract

Palmoplantar pustulosis (PPP) is a chronic inflammatory disorder characterized by sterile pustules predominantly involving the palms and soles. The purpose of this review was to describe the characteristics of Japanese PPP patients as PPP is frequently observed within the Japanese population. Most Japanese dermatologists consider PPP a distinct entity, and co-existence of PPP and psoriasis is rare; however, outside Japan, PPP is often considered to be palmoplantar psoriasis, and an extra-palmoplantar lesion associated with PPP is considered to be psoriasis. PPP frequently develops or exacerbates following focal infections such as tonsillitis, odontogenic infection, and sinusitis, either with or without arthralgia. Pustulotic arthro-osteitis (PAO) is a major comorbidity of PPP, most often affecting the anterior chest wall. In Japanese patients, PAO is frequently seen, whereas cases of SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome with symptoms other than PPP and sternocostoclavicular joint pain are extremely rare. A difference in incidence depending on race suggests that different genetic backgrounds may be responsible for susceptibility to these disorders. The treatment of focal infections often results in dramatic effects on cutaneous lesions, as well as joint pain. The characteristics of Japanese patients with PPP are female predominance, mostly smokers, rare co-existence with psoriasis, frequent association with PAO, almost no accompanying celiac disease, and closely associated with focal infection. PPP should be separately considered from palmoplantar psoriasis.

Notes

Compliance with Ethical Standards

Conflict of interest

Toshiyuki Yamamoto has no conflicts of interest to declare.

Funding

No funding sources were used to assist in the preparation of this review.

References

  1. 1.
    Andrews GC, Machacek GF. Pustular bacterids of the hands and feet. Arch Dermatol Syphilol. 1935;32:837–47.CrossRefGoogle Scholar
  2. 2.
    de Waal AC, van de Kerkhof PC. Pustulosis palmoplantaris is a disease distinct from psoriasis. J Dermatolog Treat. 2011;22:102–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Brunasso AMG, Massone C. Psoriasis and palmoplantar pustulosis: an endless debate? J Eur Acad Dermatol Venereol. 2017;31:e335–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Misiak-Galazka M, Wolska H, Rudnicka L. Is palmoplantar pustulosis simply a variant of psoriasis or a distinct entity? J Eur Acad Dermatol Venereol. 2017;31:e342–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Misiak-Galazka M, Wolska H, Rudnicka L. What do we know about palmoplantar pustulosis? J Eur Acad Dermatol Venereol. 2017;31:38–44.CrossRefPubMedGoogle Scholar
  6. 6.
    Yamamoto T. Extra-palmoplantar lesions associated with palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2009;23:1227–32.CrossRefPubMedGoogle Scholar
  7. 7.
    Brunasso AMG, Massone C. Can we really separate palmoplantar pustulosis from psoriasis? J Eur Acad Dermatol Venereol. 2010;24:619–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Yamamoto T. Can we really separate palmoplantar pustulosis from psoriasis? Reply. J Eur Acad Dermatol Venereol. 2010;24:621.CrossRefGoogle Scholar
  9. 9.
    Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5:e006450.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Akiyama T, Seishima M, Watanabe H, et al. The relationship of onset and exacerbation of pustulosis palmaris et plantaris to smoking and focal infections. J Dermatol. 1995;22:930–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Fujishiro K, Tsuboi R, Okubo Y. A statistical analysis of 111 cases of pustulosis palmaris et plantaris during the past 3 years [in Japanese]. Jpn J Dermatol. 2015;125:1775–82.Google Scholar
  12. 12.
    Hiraiwa T, Yamamoto T. Comorbidities of Japanese patients with palmoplantar pustulosis: a report from a single center. Int J Dermatol. 2018;57:e40–1.CrossRefPubMedGoogle Scholar
  13. 13.
    O’Doherty CJ, MacIntyre C. Palmoplantar pustulosis and smoking. Br Med J. 1985;291:861–4.CrossRefGoogle Scholar
  14. 14.
    Hagforsen E, Awder M, Lefvert A-K, et al. Palmoplantar pustulosis: an autoimmune disease precipitated by smoking? Acta Derm Venereol. 2002;82:341–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Giménez-Garcia R, Sánchez-Ramón S, Cuellar-Olmedo LA. Palmoplantar pustulosis: a clinicoepidemiological study. The relationship between tobacco use and thyroid function. J Eur Acad Dermatol Venereol. 2003;17:276–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Miot HA, Miot LD, Lopes PS, et al. Association between palmoplantar pustulosis and cigarette smoking in Brazil: a case-control study. J Eur Acad Dermatol Venereol. 2009;23:1173–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Michaëlsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol. 2006;54:737–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Uehara M, Ofuji S. The morphogenesis of pustulosis palmaris et plantaris. Arch Dermatol. 1974;109:518–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Krieg PHG, Bacharach-Buhles M, el-Gammal S, Altmeyer P. The pustule in palmoplantar psoriasis: transformed vesicle or mature microabscess? Dermatology. 1992;185:104–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Engin B, Aşkin Ö, Tüzün Y. Palmoplantar psoriasis. Clin Dermatol. 2017;35:19–27.CrossRefPubMedGoogle Scholar
  21. 21.
    Burden AD, Kemmett D. The spectrum of nail involvement in palmoplantar pustulosis. Br J Dermatol. 1996;134:1079–82.CrossRefPubMedGoogle Scholar
  22. 22.
    Hiraiwa T, Yamamoto T. Nail involvement associated with palmoplantar pustulosis. Int J Dermatol. 2017;56:e28–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Baran R. The burden of nail psoriasis: an introduction. Dermatology. 2010;221(Suppl 1):1–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Becher G, Jamieson L, Leman J. Palmoplantar pustulosis-a retrospective review of comorbid conditions. J Eur Acad Dermatol Venereol. 2015;29:1854–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Yamamoto T. Pustulotic arthro-osteitis associated with palmoplantar pustulosis. J Dermatol. 2013;40:857–63.CrossRefPubMedGoogle Scholar
  26. 26.
    Torii H, Nakagawa H, Ishibashi Y. Osteoarthritis in 84 Japanese patients with palmoplantar pustulosis. J Am Acad Dermatol. 1994;31:732–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Ishibashi A, Nishiyama Y, Endo M, et al. Orthopdic symptoms in pustular bacterid (pustulosis palmaris et plantaris): Tietze’s syndrome and arthritis of manubriosternal joint due to focal infection. J Dermatol. 1977;4:53–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Ohashi T, Hiraiwa T, Yamamoto T. Low prevalence of anti-cyclic citrullinated peptide antibodies in Japanese patients with pustulotic arthro-osteitis. Indian J Dermatol. 2016;61:221–2.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Michaëlsson G, Kristjánsson G, Lundin IP, Hagforsen E. Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. Br J Dermatol. 2007;156:659–66.CrossRefPubMedGoogle Scholar
  30. 30.
    Heymann WR. Cutaneous manifestations of thyroid disease. J Am Acad Dermatol. 1992;26:885–902.CrossRefPubMedGoogle Scholar
  31. 31.
    Ai J, Leonhardt JM, Heymann WR. Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations. J Am Acad Dermatol. 2003;48:641–59.CrossRefPubMedGoogle Scholar
  32. 32.
    Seno A, Arata J, Matsuura Y, Suemitsu I. Palmoplantar pustulosis with pustulotic arthroosteitis involving temporal osteomyelitis and meningitis. J Dermatol. 2000;27:269–72.CrossRefPubMedGoogle Scholar
  33. 33.
    Hiraiwa T, Rokkaku Y, Yamamoto T. Palmoplantar pustulosis with arthro-osteitis triggered by recurrent appendeal abscess 5 years after appendectomy. Int J Dermatol. 2014;53:e242–3.CrossRefPubMedGoogle Scholar
  34. 34.
    Kikuchi N, Yamamoto T. Dental infection as a triggering factor in palmoplantar pustulosis. Acta Derm Venereol. 2013;93:721–2.CrossRefPubMedGoogle Scholar
  35. 35.
    Tsan M-F, Gao B. Heat shock protein and innate immunity. Cell Mol Immunol. 2004;1:274–9.PubMedGoogle Scholar
  36. 36.
    Izaki S, Goto Y, Kaburagi Y, et al. Antibody production to heat shock proteins with Mr 65 kD (HDP65) in cutaneous inflammation: a possible relation to focal infection. Acta Otolaryngol (Suppl). 1996;523:197–200.Google Scholar
  37. 37.
    Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129:2175–83.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Lillis JV, Guo C-S, Lee JJ, Blauvelt A. Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis. Arch Dermatol. 2010;146:918–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Hagforsen E, Hedstrand H, Nyberg F, Michaëlsson G. Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br J Dermatol. 2010;163:572–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Murakami M, Hagforsen E, Morhenn V, et al. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20:845–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Kataura A, Tsubota H. Clinical analyses of focus tonsil and related diseases in Japan. Acta Otolaryngol Suppl. 1996;523:161–4.PubMedGoogle Scholar
  42. 42.
    Nozawa H, Kishibe K, Takahara M, Harabuchi Y. Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP). Clin Immunol. 2005;116:42–53.CrossRefPubMedGoogle Scholar
  43. 43.
    Murakata H, Harabuchi Y, Kataura A. Increased interleukin-6, interferon-gamma and tumor necrosis factor-alpha production by tonsillar mononuclear cells stimulated with alpha-streptococci in patients with pustulosis palmaris et plantaris. Acta Otolaryngol. 1999;119:384–91.CrossRefPubMedGoogle Scholar
  44. 44.
    Yoshizaki T, Bandoh N, Ueda S, et al. Up-regulation of CC chemokine receptor 6 on tonsillar T cells and its induction by in vitro stimulation with α-streptococci in patients with pustulosis palmaris et plantaris. Clin Exp Immunol. 2009;157:71–82.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Sakiyama H, Kobayashi S, Dianzani U, et al. Possible involvement of T cell co-stimulation in pustulosis palmaris et plantaris via the induction of inducible co-stimulator in chronic focal infections. J Dermatol Sci. 2008;50:197–207.CrossRefPubMedGoogle Scholar
  46. 46.
    Moutsopoulos NM, Kling HM, Angelov N, et al. Porphyromonas gingivalis promotes Th17 inducing pathways in chronic periodontitis. J Autoimmun. 2012;39:294–303.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Yamamoto T, Yokozeki H, Tsuboi R. Koebner’s phenomenon associated with palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2007;21:990–2.CrossRefPubMedGoogle Scholar
  48. 48.
    Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol. 2003;120:627–32.CrossRefPubMedGoogle Scholar
  49. 49.
    Kingo K, Mӧssner R, Kõks S, et al. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol. 2007;156:646–52.CrossRefPubMedGoogle Scholar
  50. 50.
    Takahashi T, Fujimoto N, Kabuto M, et al. Mutation analysis of IL-36RN gene in Japanese patients with palmoplantar pustulosis. J Dermatol. 2017;44:80–3.CrossRefPubMedGoogle Scholar
  51. 51.
    Wang T-S, Chiu H-Y, Hong J-B, et al. Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients. Arch Dermatol Res. 2016;308:55–63.CrossRefPubMedGoogle Scholar
  52. 52.
    Nakamura K, Imakado S, Takizawa M, et al. Exacerbation of pustulosis palmaris et plantaris after topical application of metals accompanied by elevated levels of leukotriene B4 in pustules. J Am Acad Dermatol. 2000;42:1021–5.CrossRefPubMedGoogle Scholar
  53. 53.
    Yanagi T, Shimizu T, Abe R, Shimizu H. Zinc dental fillings and palmoplantar pustulosis. Lancet. 2005;366:1050.CrossRefPubMedGoogle Scholar
  54. 54.
    Kouno M, Nishiyama A, Minabe M, et al. Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal. J Dermatol. 2017;44:695–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Minang JT, Areström I, Troye-Blomberg M, et al. Nickel, cobalt, chromium, paradium and gold induce a mixed Th1- and Th2-type cytokine response in vitro in subjects with contact allergy to the respective metals. Clin Exp Immunol. 2006;146:417–26.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Kuroishi T. Regulation of immunological and inflammatory functions by biotin. Can J Physiol Pharmacol. 2015;93:1091–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Laan M, Cui ZH, Hoshino H, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol. 1999;162:2347–52.PubMedGoogle Scholar
  58. 58.
    Murakami M, Kaneko T, Nakatsuji T, et al. Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. PLoS One. 2014;9:e110677.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Skov L, Beurskens FJ, Zachariae COC, et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol. 2008;181:669–79.CrossRefPubMedGoogle Scholar
  60. 60.
    Ozawa M, Terui T, Tagami H. Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. Dermatology. 2005;211:249–55.CrossRefPubMedGoogle Scholar
  61. 61.
    Keller M, Spanou Z, Schaerli P, et al. T cell-regulated neutrophilic inflammation in autoinflammatory diseases. J Immunol. 2005;175:7678–86.CrossRefPubMedGoogle Scholar
  62. 62.
    Eriksson MO, Hagforsen Lundin IP, Michaëlsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol. 1998;138:390–8.CrossRefPubMedGoogle Scholar
  63. 63.
    Murakami M, Ohtake T, Horibe Y, et al. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol. 2010;130:2010–6.CrossRefPubMedGoogle Scholar
  64. 64.
    Hagforsen E, Michaëlsson G, Stridsberg M. Normal and PPP-affected palmoplantar sweat gland express neuroendocrine markers chromogranins and synaptophysin differently. Arch Dermatol Res. 2010;302:685–93.CrossRefPubMedGoogle Scholar
  65. 65.
    Hagforsen E. The cutaneous non-neuronal cholinergic system and smoking related dermatoses: studies of the psoriasis variant palmoplantar pustulosis. Life Sci. 2007;80:2227–34.CrossRefPubMedGoogle Scholar
  66. 66.
    Hagforsen E, Edvinsson M, Nordlind K, Michaëlsson G. Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J Dermatol. 2002;146:383–91.CrossRefPubMedGoogle Scholar
  67. 67.
    Johnson GK, Guthmiller JM, Joly S, et al. Interleukin-1 and interleukin-8 in nicotine- and lipopolysaccharide-exposed gingival keratinocyte cultures. J Periodontal Res. 2010;45:583–8.PubMedGoogle Scholar
  68. 68.
    Tsuji G, Takahara M, Uchi H, et al. An environmental contaminant, benzo(a)pyrene, induces oxidative stress-mediated interleukin-8 production in human keratinocytes via the aryl hydrocarbon receptor signaling pathway. J Dermatol Sci. 2011;62:42–9.PubMedGoogle Scholar
  69. 69.
    Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008;453:106–9.CrossRefPubMedGoogle Scholar
  70. 70.
    Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453:65–71.CrossRefPubMedGoogle Scholar
  71. 71.
    Yamin M, Holbrook EH, Gray ST, et al. Cigarette smoke combined with Toll-like receptor 3 signaling triggers exaggerated epithelial regulated upon activation, normal T-cell expressed and secreted/CCL5 expression in chronic rhinosinusitis. J Allergy Clin Immunol. 2008;122:1145–53.CrossRefPubMedGoogle Scholar
  72. 72.
    Fatourechi V. Demystifying autoimmune thyroid disease: which disorders require treatment? Postgrad Med. 2000;107:127–34.CrossRefPubMedGoogle Scholar
  73. 73.
    Edlund E, Johnsson U, Lidgren L, et al. Palmoplantar pustulosis and sternocostoclavicular arthro-osteitis. Ann Rheum Dis. 1988;47:809–15.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Valeri M, Raffatellu M. Cytokines IL-17 and IL-22 in the host response to infection. Pathog Dis. 2016;74:ftw111.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    El-Zayadi AA, Jones EA, Churchman SM, et al. Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology. 2017;56:488–93.PubMedGoogle Scholar
  76. 76.
    Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202–9.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Chen G, Deng C, Li Y-P. TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 2012;8:272–88.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Kragballe K, Larsen FG. A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to Clobetasol cream in palmo-plantar pustulosis. Acta Derm Venereol. 1991;71:540–2.PubMedGoogle Scholar
  79. 79.
    Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: a review. Int J Dermatol. 2015;54:383–92.CrossRefPubMedGoogle Scholar
  80. 80.
    Yamanaka KI, Kakeda M, Kitagawa H, Tsuda K, Akeda T, Kurokawa I, Gabazza EC, Kupper TS, Mizutani H. 1,24-Dihydroxyvitamin D3 (tacalcitol) prevents skin T-cell infiltration. Br J Dermatol. 2010;162:1206–15.CrossRefPubMedGoogle Scholar
  81. 81.
    Umezawa Y, Nakagawa H, Tamaki K. Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: a randomized, double-blind, placebo-controlled trial. J Dermatol. 2016;43:288–93.CrossRefPubMedGoogle Scholar
  82. 82.
    Muro M, Kawakami H, Matsumoto Y, et al. Topical combination therapy with vitamin D3 and corticosteroid ointment for palmoplantar pustulosis: a prospective, randomized, left-right comparison study. J Dermatolog Treat. 2016;27:51–3.CrossRefPubMedGoogle Scholar
  83. 83.
    Sehgal VN, Srivastava G, Dogra S. Tacrolimus in dermatology-pharmacokinetics, mechanism of action, drug interaction, dosages, and side effects: part I. Skinmed. 2008;7:27–30.CrossRefPubMedGoogle Scholar
  84. 84.
    Lan CC, Yu HS, Wu CS, et al. FK506 inhibits tumor necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappaB. Br J Dermatol. 2005;153:725–32.CrossRefPubMedGoogle Scholar
  85. 85.
    Laino L, DiCarlo A. Palmoplantar pustular psoriasis: clinical and video thermographic evaluation before and after topical tacrolimus treatment. Arch Dermatol. 2011;147:760.CrossRefPubMedGoogle Scholar
  86. 86.
    Furuhashi T, Torii K, Kato H, et al. Efficacy of excimer light therapy (308 nm) for palmoplantar pustulosis with the induction of circulating regulatory T cells. Exp Dermatol. 2011;20:768–70.CrossRefPubMedGoogle Scholar
  87. 87.
    Kawada A, Matsuda H, Oiso N. Efficacy and safety of targeted narrowband ultraviolet B therapy using a flat-type fluorescent lamp for the treatment of palmoplantar pustulosis. J Dermatol. 2013;40:754–5.CrossRefPubMedGoogle Scholar
  88. 88.
    Fumimori T, Tsuruta D, Kawakami T, et al. Effect of monochromatic excimer light on palmoplantar pustulosis: a clinical study performed in a private clinic by a dermatological specialist. J Dermatol. 2013;40:1004–7.CrossRefPubMedGoogle Scholar
  89. 89.
    Su LN, Ren J, Cheng SM, et al. UVA vs. narrowband UVB phototherapy in the treatment of palmoplantar pustulosis: a pilot randomized controlled study. Lasers Med Sci. 2017;32:1819–23.CrossRefPubMedGoogle Scholar
  90. 90.
    Raverdeau M, Mills KHG. Modulation of T cell and innate immune responses by retinoic acid. J Immunol. 2014;192:2953–8.CrossRefPubMedGoogle Scholar
  91. 91.
    Irla N, Navarini AA, Yawalkar N. Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis. Br J Dermatol. 2012;167:1170–4.CrossRefPubMedGoogle Scholar
  92. 92.
    Reich K, Graff O, Mehta N. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study. Br J Dermatol. 2016;174:1277–81.CrossRefPubMedGoogle Scholar
  93. 93.
    Wilken R, Sharma A, Patel F, Maverakis E. Successful treatment of palmoplantar pustulosis with isotretinoin. Dermatol Online J. 2015;21:14.Google Scholar
  94. 94.
    Shan S-J, Li Y-H, Zhang G, et al. Treatment of palmoplantar pustulosis with arotinoid ethylester. Eur J Dermatol. 2009;19:474–7.PubMedGoogle Scholar
  95. 95.
    Erkko P, Granlund H, Remitz A, et al. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol. 1998;139:997–1004.CrossRefPubMedGoogle Scholar
  96. 96.
    Yamamoto T, Nishioka K. Severe extra-palmoplantar pustulation associated with palmoplantar pustulosis. J Dermatol. 2004;31:690–2.CrossRefPubMedGoogle Scholar
  97. 97.
    Yamamoto T, Kimura K, Katayama I, Nishioka K. Successful treatment of severe arthralgia associated with palmoplantar pustulosis with low-dose oral cycloporine A. J Dermatol. 1995;22:512–4.CrossRefPubMedGoogle Scholar
  98. 98.
    Vaccaro M, Borgia F, Guarneri F, et al. Successful treatment of pustulotic arthro-osteitis (Sonozaki syndrome) with systemic cyclosporin. Clin Exp Dermatol. 2001;26:45–7.CrossRefPubMedGoogle Scholar
  99. 99.
    Hayama K, Inadomi T, Fujisawa D, Terui T. A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis. Eur J Dermatol. 2010;20:758–62.PubMedGoogle Scholar
  100. 100.
    Mrowietz U, van de Kerkhof PCM. Management of palmoplantar pustulosis: do we need to change? Br J Dermatol. 2011;164:942–6.CrossRefPubMedGoogle Scholar
  101. 101.
    Adisen E, Tekin O, Gülekon A, Gürer MA. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol. 2009;23:814–9.CrossRefPubMedGoogle Scholar
  102. 102.
    Stanford CW, Kollipara R, Melookaran AM, Hall JC. Palmoplantar pustular psoriasis following initiation of a beta-blocker: disease control with low-dose methotrexate. Cutis. 2014;94:153–5.PubMedGoogle Scholar
  103. 103.
    Thomsen K, Osterbye P. Pustulosis palmaris et plantaris. Br J Dermatol. 1973;89:293–6.CrossRefPubMedGoogle Scholar
  104. 104.
    Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol. 1986;86:449–53.CrossRefPubMedGoogle Scholar
  105. 105.
    Murakami M, Masuda K, Utsunomiya R, et al. Cefcapene pivoxil hydrochloride is a potentially new treatment for palmoplantar pustulosis with pustulotic arthro-osteitis. Dermatology. 2015;231:304–11.CrossRefPubMedGoogle Scholar
  106. 106.
    Angelidis C, Kotsialou Z, Kossyvakis C, et al. Colchicine pharmacokinetics and mechanism of action. Curr Pharm Des. 2018;24:659–63.CrossRefPubMedGoogle Scholar
  107. 107.
    Takigawa M, Miyachi Y, Uehara M, Tagami H. Treatment of pustulosis palmaris et plantaris with oral doses of colchicine. Arch Dermatol. 1982;118:458–60.CrossRefPubMedGoogle Scholar
  108. 108.
    Thestrup-Pedersen K, Reymann F. Treatment of pustulosis palmaris et plantaris with colchicine. Acta Derm Venereol. 1984;64:76–8.PubMedGoogle Scholar
  109. 109.
    Wong SS, Tan KC, Goh CL. Long-term colchicine for recalcitrant palmoplantar pustulosis: treatment outcome in 3 patients. Cutis. 2001;68:216–8.PubMedGoogle Scholar
  110. 110.
    Hayashi S, Shimaoka Y, Hamasaki Y, Hatamochi A. Palmoplantar pustulosis and pustulotic arthro-osteitis treatment with potassium iodide and tetracycline, a novel remedy with an old drug: a review of 25 patients. Int J Dermatol. 2017;56:889–93.CrossRefPubMedGoogle Scholar
  111. 111.
    Mihara M, Hagari Y, Morimura T, et al. Itraconazole as a new treatment for pustulosis palmaris et plantaris. Arch Dermatol. 1998;134:639–40.CrossRefPubMedGoogle Scholar
  112. 112.
    V’lckova-Laskoska MT, Caca-Biljanovska NG, Laskoski DS, Kamberova SJ. Palmoplantar pustulosis treated with itraconazole: a single, active-arm pilot study. Dermatol Ther. 2009;22:85–9.CrossRefPubMedGoogle Scholar
  113. 113.
    Buder V, Herberger K, Jacobi A, et al. Ustekinumab in the treatment of palmoplantar pustular psoriasis: a case series of nine patients. J Dtsch Dermatol Ges. 2016;14:1108–13.CrossRefPubMedGoogle Scholar
  114. 114.
    Morales-Múnera C, Vilarrasa E, Puig L. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol. 2013;168:820–4.CrossRefPubMedGoogle Scholar
  115. 115.
    Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol. 2010;163:1116–8.CrossRefPubMedGoogle Scholar
  116. 116.
    De Unamuno-Bustos B, Ballester-Sánchez R, Oliver-Martinez V, de Miquel AV. Ustekinumab for the treatment of palmar-plantar pustulosis. Actas Dermosifiliogr. 2011;102:833–5.CrossRefPubMedGoogle Scholar
  117. 117.
    Ohashi T, Suzuki Y, Yamamoto T. Use of biologics for pustulotic arthro-osteitis in two patients with palmoplantar pustulosis. J Dermatol. 2017;44:97–8.CrossRefPubMedGoogle Scholar
  118. 118.
    Hegazy S, Konstantinou MP, Bulai Livideanu C, et al. Efficacy of ustekinumab in palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2018;32:e204–6.CrossRefPubMedGoogle Scholar
  119. 119.
    Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial. JAMA Dermatol. 2018;154:309–16.CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Guenther LC. Alefacept is safe and efficacious in the treatment of palmoplantar pustulosis. J Cutan Med Surg. 2007;11:202–5.CrossRefPubMedGoogle Scholar
  121. 121.
    Carr D, Tusa MG, Carroll CL, et al. Open label trial of alefacept in palmoplantar pustular psoriasis. J Dermatol Treat. 2008;19:97–100.CrossRefGoogle Scholar
  122. 122.
    Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67:e179–85.CrossRefPubMedGoogle Scholar
  123. 123.
    Torre KM, Payette MJ. Combination biologic therapy for the treatment of severe palmoplantar pustulosis. JAAD Case Rep. 2017;3:240–2.CrossRefPubMedPubMedCentralGoogle Scholar
  124. 124.
    Fujisawa T, Tawada C, Mizutani Y, et al. Efficacy of granulocyte and monocyte adsorption apheresis for treatment of palmoplantar pustulosis. Ther Apher Dial. 2014;18:238–43.CrossRefPubMedGoogle Scholar
  125. 125.
    Sakanoue M, Takeda K, Kawai K, Kanekura T. Granulocyte and monocyte adsorption apheresis for refractory skin diseases due to activated neutrophils, psoriasis and associated arthropathy. Ther Apher Dial. 2013;17:477–83.CrossRefPubMedGoogle Scholar
  126. 126.
    Arimura A, Fujii K, Ibusuki A, et al. Granulocyte and monocyte adsorption apheresis for palmoplantar pustulosis with extra-palmoplantar lesions and pustulotic arthro-osteitis. J Dermatol. 2018;45:e167–8.CrossRefPubMedGoogle Scholar
  127. 127.
    Kashiwagi N, Sugimura K, Koiwai H, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci. 2002;47:1334–41.CrossRefPubMedGoogle Scholar
  128. 128.
    Ono T, Jono M, Kito M, et al. Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris. Acta Otolaryngol Suppl. 1983;401:12–6.CrossRefPubMedGoogle Scholar
  129. 129.
    Yokoyama M, Hashiguchi K, Yamasaki Y. Effect of tonsillectomy in patients with pustulosis palmaris et plantaris. Acta Otolaryngol. 2004;124:1109–10.CrossRefPubMedGoogle Scholar
  130. 130.
    Takahara M, Hirata Y, Nagato T, et al. Treatment outcome and prognostic factors of tonsillectomy for palmoplantar pustulosis and pustulotic arthro-osteitis: a retrospective sunjective and objective quantitative analysis of 138 patients. J Dermatol. 2018;45:812–23.CrossRefPubMedGoogle Scholar
  131. 131.
    Yamamoto T. Triggering role of focal infection in the induction of extra-palmoplantar lesions and pustulotic arthro-osteitis associated with palmoplantar pustulosis. Adv Otorhinolaryngol. 2011;72:89–92.PubMedGoogle Scholar
  132. 132.
    Yamamoto T, Katayama I, Nishioka K. Restricted usage of the T-cell receptor Vβ repertoire in tonsillitis in association with palmoplantar pustulosis. Acta Derm Venereol (Stockh). 1998;78:161–3.CrossRefGoogle Scholar
  133. 133.
    Trattner H, Blüml S, Steiner I, et al. Quality of life and comorbidities in palmoplantar pustulosis: a cross-sectional study on 102 patients. J Eur Acad Dermatol Venereol. 2017;31:1681–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of DermatologyFukushima Medical UniversityFukushimaJapan

Personalised recommendations